In:
Dementia and Geriatric Cognitive Disorders, S. Karger AG, Vol. 19, No. 5-6 ( 2005), p. 229-245
Kurzfassung:
Ten years after the introduction of the first drug, tacrine, in the treatment of Alzheimer’s disease, it seems appropriate to reappraise the pharmacological processes of innovation in the research field of dementia. The aim of this review is to pinpoint concrete improvements achieved in this field, regarding experimental methods and clinical evaluation of the compounds, as well as the neurochemistry of the disease and cellular targets to consider in priority. This review deals with this objective in three parts: (1) assessment of current therapeutics, (2) discussion of the experimental models and clinical practices and (3) prospective drugs of the future. The implementation of considered strategies will require the involvement and close cooperation between political decisions, pharmaceutical companies and the scientific community.
Materialart:
Online-Ressource
ISSN:
1420-8008
,
1421-9824
Sprache:
Englisch
Verlag:
S. Karger AG
Publikationsdatum:
2005
ZDB Id:
1482186-2
